Effects of a semi-synthetic N-,O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischaemia/ reperfusion injury

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 837-845

  Collino, Massimo ^a   Castiglia, Sara ^a   Manoni, Marco ^b   Salsini, Liana ^b   Chini, Jacopo ^b   Masini, Emanuela ^c   Fantozzi, Roberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b INALCO RSM SpA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cerebral ischaemia reperfusion; Heparin like derivative; Hippocampus; Inflammation

Indexed keywords

BACTERIAL POLYSACCHARIDE; HEPARIN; K5 N,O SEPI; LOW MOLECULAR WEIGHT HEPARIN; N,O SULFATED K5 POLYSACCHARIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; ENZYME MODIFICATION; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BRAIN DAMAGE, CHRONIC; BRAIN ISCHEMIA; CHEMOTAXIS, LEUKOCYTE; CYCLOOXYGENASE 2; DRUG EVALUATION, PRECLINICAL; HIPPOCAMPUS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MALE; NEUTROPHILS; NITRIC OXIDE SYNTHASE TYPE II; POLYSACCHARIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; PSYCHOMOTOR PERFORMANCE; RANDOM ALLOCATION; RATS; RATS, WISTAR; REPERFUSION INJURY; TRANSCRIPTION FACTOR RELA;

EID: 70449594753     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-01-0012     Document Type: Conference Paper

References (42)

1. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007; 54: 34-66. (Pubitemid 46498164)
2. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007; 97: 738-747.
3. Sandercock P. Immediate anticoagulation for acute stroke in atrial fibrillation: no. Stroke 2006; 37: 3054-3055.
4. Bousser MG. Antithrombotic strategy in stroke. Thromb Haemost 2001; 86: 1-7.
5. Floris S, van den Born J, van der Pol SM, et al. Heparan sulfate proteoglycans modulate monocyte migration across cerebral endothelium. J Neuropathol Exp Neurol 2003; 62: 780-790. (Pubitemid 36870462)
6. Attanasio M, Gori AM, Giusti B, et al. Cytokine gene expression in human LPS- and IFNgamma-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 1998; 79: 959-962. (Pubitemid 28224732)
7. Hochart H, Jenkins PV, Preston RJ, et al. Concentration- dependent roles for heparin in modifying lipopolysaccharide- induced activation of mononuclear cells in whole blood. Thromb Haemost 2008; 99: 570-575. (Pubitemid 351549294)
8. Rusnati M, Oreste P, Zoppetti G, et al. Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. Curr Pharm Des 2005; 11: 2489-2499. (Pubitemid 40872693)
9. Thourani VH, Brar SS, Kennedy TP, et al. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2000; 278: H2084-93.
10. Gori AM, Attanasio M, Gazzini A, et al. Cytokine gene expression and production by human LPS-stimulated mononuclear cells are inhibited by sulfated heparin- like semi-synthetic derivatives. J Thromb Haemost 2004; 2: 1657-1662. (Pubitemid 40186184)
11. Wan JG, Mu JS, Zhu HS, et al. N-desulfated nonanticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Inflamm Res 2002; 51: 435-443.
12. Kouretas PC, Kim YD, Cahill PA, et al. Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. Circulation 1999; 99: 1062-1068.
13. Zhou T, Chen JL, Song W, et al. Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats. World J Gastroenterol 2002; 8: 897-900.
14. Collino M, Aragno M, Mastrocola R, et al. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med 2006; 41: 579-589. (Pubitemid 44080506)
15. Collino M, Aragno M, Castiglia S, et al. Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3{beta}. Diabetes 2009; 58: 235-242.
16. Manzoni M. BS, Cavazzoni V. Extracellular K5 polysaccharide of Escherichia coli: production and characterization. Journal of Bioactive and compatible polymers 1993; 8: 251-257. (Pubitemid 23241795)
17. Horton DP, K.D. The nitrous acid deamination of glycosides and acetates of 2-amino-2-deoxy-. D. - glucose. . Carbohydr Res 1973; 30: 367-373.
18. Guerrini M, Bisio A, Torri G. Combined quantitative (1)H and (13)C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin Thromb Hemost 2001; 27: 473-482. (Pubitemid 32989371)
19. Meldrum DR, Shenkar R, Sheridan BC, et al. Hemorrhage activates myocardial NFkappaB and increases TNF-alpha in the heart. J Mol Cell Cardiol 1997; 29: 2849-2854. (Pubitemid 27466506)
20. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002;7: d1356-1368.
21. Foerch C, Singer OC, Neumann-Haefelin T, et al. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005; 62: 1130-1134. (Pubitemid 41043736)
22. del Zoppo GJ. Stroke and neurovascular protection. N Engl J Med 2006; 354: 553-555.
23. Sharma BK, Kumar K. Role of proinflammatory cytokines in cerebral ischemia: a review. Metab Brain Dis 1998; 13: 1-8. (Pubitemid 28185766)
24. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 2002; 33: 2115-2122.
25. Liu SJ, Zhou SW, Xue CS. Effect of tetrandrine on neutrophilic recruitment response to brain ischemia/ reperfusion. Acta Pharmacol Sin 2001; 22: 971-975. (Pubitemid 33593637)
26. Storini C, Rossi E, Marrella V, et al. C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis 2005; 19: 10-17. (Pubitemid 40544719)
27. Wang YH, Wang WY, Chang CC, et al. Taxifolin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation. J Biomed Sci 2006; 13: 127-141. (Pubitemid 43162511)
28. Silvestro L, Viano I, Macario M, et al. Effects of heparin and its desulfated derivatives on leukocyte-endothelial adhesion. Semin Thromb Hemost 1994; 20: 254-258. (Pubitemid 24287453)
29. Suzuki Y, Takagi Y, Kawano K, et al. A novel guinea pig model with cyclic flow reductions following thrombotic cerebral ischemia. Brain Res Brain Res Protoc 2002; 10: 55-59. (Pubitemid 35335970)
30. Stevens SL, Bao J, Hollis J, et al. The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res 2002; 932: 110-119. (Pubitemid 34241600)
31. Ceccarelli M, Bani D, Cinci L, et al. Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of Carrageenan-induced pleurisy. J Cell Mol Med 2009; epub ahead of print PMID: 19175471.
32. Nichols TC. NF-kappaB and reperfusion injury. Drug News Perspect 2004; 17: 99-104.
33. Shen WH, Zhang CY, Zhang GY. Antioxidants attenuate reperfusion injury after global brain ischemia through inhibiting nuclear factor-kappa B activity in rats. Acta Pharmacol Sin 2003; 24: 1125-1130.
34. Collino M, Thiemermann C, Mastrocola R, et al. Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/ reperfusion injury in the rat hippocampus. Shock 2008; 30: 299-307.
35. Hochart H, Jenkins PV, Smith OP, et al. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 2006; 133: 62-67. (Pubitemid 43327199)
36. Antonsson B, Conti F, Ciavatta A, et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997; 277: 370-372. (Pubitemid 27450709)
37. Plesnila N, Zinkel S, Le DA, et al. BID mediates neuronal cell death after oxygen/ glucose deprivation and focal cerebral ischemia. Proc Natl Acad Sci U S A 2001; 98: 15318-15323. (Pubitemid 34014012)
38. Yin XM, Luo Y, Cao G, et al. Bid-mediated mitochondrial pathway is critical to ischemic neuronal apoptosis and focal cerebral ischemia. J Biol Chem 2002; 277: 42074-42081. (Pubitemid 35257522)
39. Lam M, Bhat MB, Nunez G, et al. Regulation of Bcl-xl channel activity by calcium. J Biol Chem 1998; 273: 17307-17310. (Pubitemid 28355053)
40. Sato T, Hanada M, Bodrug S, et al. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci U S A 1994; 91: 9238-9242. (Pubitemid 24297889)
41. Zhao H, Yenari MA, Cheng D, et al. Bcl-2 overexpression protects against neuron loss within the ischemic margin following experimental stroke and inhibits cytochrome c translocation and caspase-3 activity. J Neurochem 2003; 85: 1026-1036. (Pubitemid 36578634)
42. Brambrink AM, Schneider A, Noga H, et al. Tolerance- Inducing dose of 3-nitropropionic acid modulates bcl-2 and bax balance in the rat brain: a potential mechanism of chemical preconditioning. J Cereb Blood Flow Metab 2000; 20: 1425-1436. (Pubitemid 30770219)